Screener
Integra LifeSciences IART Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable, accrued expenses and other current liabilities | (34,384) | (2,078) |
| Contract liabilities | (1,392) | 2,344 |
| Other non-current liabilities | 1,205 | 2,544 |
| Net cash provided by (used in) operating activities | 32,605 | (2,338) |
| INVESTING ACTIVITIES: | ||
| Purchases of property and equipment | (27,155) | (49,066) |
| Purchases of short-term investments | (30,976) | (8,502) |
| Net cash used in investing activities | (58,131) | (57,568) |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's operating cash flow?
- Integra LifeSciences (IART) reported operating cash flow of $22.8M in Q2 2026.
- How has Integra LifeSciences's operating cash flow changed year-over-year?
- Integra LifeSciences's operating cash flow increased by 155.7% year-over-year, from $8.92M to $22.8M.
- What is the long-term trend for Integra LifeSciences's operating cash flow?
- Over 4 years (2021 to 2025), Integra LifeSciences's operating cash flow has grown at a -36.6% compound annual growth rate (CAGR), from $312.43M to $50.38M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Integra LifeSciences's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude